All
Support Patient Access and Education with the End Brain Cancer Initiative for GiveBIG 2025
People can help EBCI reach their goal of $20,000 dollars raised for GiveBIG 2025 by giving at endbraincancer.org/donate.
Remission is Not a Cure for Follicular Lymphoma, or Any Cancer
It’s spring, a time for new beginnings following a cancer diagnosis; however, I have an ongoing issue that I can’t dismiss.
First Patient with CD5-Positive T-Cell Lymphoma Dosed with MB-105
The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.
Oncodetect Test Aims to Detect Recurrence Risk Across Solid Tumors
The Oncodetect test detects molecular residual disease across solid tumors using circulating tumor DNA to inform recurrence risk and treatment decisions.
Imfinzi Combination Shows Efficacy in Bladder Cancer Treatment
Dr. Matthew Galsky discusses the FDA approval of Imfinzi and chemo before and after surgery for muscle-invasive bladder cancer, based on the NIAGARA trial.
Aspiring to Make a Difference for Immigrants
“Don’t aspire to make a living. Let’s aspire to make a difference in the Mandarin/Cantonese-speaking community.”
Raising Awareness for Adolescents and Young Adults with Cancer
Carly Stafford Dixon, a rare cancer survivor, highlights the need for AYA cancer awareness to improve support, visibility and access to vital resources.
Clinical Trials Enhance Care for Advanced Gastrointestinal Cancers
Clinical trials improve care and access to novel treatments for advanced gastrointestinal cancers, says Dr. Michael Pishvaian.
My 11-Year Metastatic Breast Cancer Story Defied the Standard Path
Diagnosed in 2014, I share my unique aggressive treatment journey over 11 years, highlighting a common hope for more time and better treatments.
Enhertu Combo Improves Progression in HER2+ Metastatic Breast Cancer
Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive metastatic breast cancer.
Trodelvy Plus Keytruda May Slow Progression in mTNBC
In some patients with advanced triple-negative breast cancer, Trodelvy plus Keytruda was associated with an improvement in disease progression.
Pausing BTKi for Vaccine Did Not Boost Immunity in CLL
Pausing treatment during vaccination did not improve immunity in patients with chronic lymphocytic leukemia and should not be recommended, a trial found.
“Chillin’ Out” and Finding Our Cancer Community
After nearly 30 years with cancer — community, research and education have helped us find hope, strength and purpose in the face of chronic blood cancers.
Bavencio Maintains Bladder Cancer Benefit in Patients with Diabetes
Bavencio improved survival in patients with bladder cancer, irrespective of diabetes status, according to an analysis of the JAVELIN Bladder 100 trial.
Optimal Jakafi Dosing Associated With Improved Outcomes in Myelofibrosis
Optimal dosing of Jakafi was associated with improved efficacy and manageable safety in patients with myelofibrosis, according to the ROMEI clinical trial.
Illuminating Compassion in Cancer Care
The journey that led to the creation of the Extraordinary Healer Award for Oncology Nursing began with a simple, yet profound, observation.
Renowned Breast Cancer Physician-Scientist Dr. Hope S. Rugo to Lead City of Hope’s Women’s Cancers Program
Dr. Rugo has led key breast cancer therapy trials and exudes a passion for serving patients.
Reassessing Immunotherapy Use in Advanced Renal Cell Carcinoma
There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were treated in the advanced setting.
Recognizing Symptoms During Head and Neck Cancer Awareness Month
Dr. Zafar Sayed discuss the importance of recognizing Head and Neck Cancer Awareness Month and highlights early symptoms of the disease to be aware of.
AI Tool May Better Predict Transplant Risk in Myelofibrosis
An AI model may help identify patients with myelofibrosis at high risk of early death after transplant, according to an expert.
Daffodils and Determination from a Patient with Chronic Lymphocytic Leukemia
Each spring, I find strength and hope in the daffodils I grow, helping me face chronic lymphocytic leukemia with renewed determination.
First Patient Dosed in a Phase 1/2 Trial for Small Cell Lung Cancer
The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus immune checkpoint inhibitors.
First Patient with Colon Cancer Dosed in a Phase 2 Study of TCMCB07
The first patient has received TCMCB07 in a phase 2 trial to prevent weight loss in patients with metastatic colorectal cancer undergoing chemotherapy.
Radiation Delay in NSCLC May Aid Outcomes, But Raises Toxicity Risks
Deferring upfront CNS-directed radiation in EGFR-variant and ALK-positive NSCLC may improve outcomes but raises treatment-related toxicity risks.
Radiation Therapy Now More Targeted and Tolerable in GI Cancer
Radiation therapy for gastrointestinal cancers is more precise and easier to tolerate due newer technologies and personalized care, according to experts.
Dr. Grivas Highlights Three Practice-Changing Trials in Bladder Cancer
Dr. Petros Grivas discusses the importance of tailoring treatment decisions in bladder cancer based on data from three practice-changing phase 3 trials.
Antibody-Drug Conjugates Changed the Standard of Care in Bladder Cancer
Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, replacing single-agent treatments.
New Jersey Patients Receiving First-of-Its-Kind Catheter Based Pancreatic Cancer Treatment
Experts at Hackensack Meridian Jersey Shore University Medical Center have successfully treated their first patients using the TAMP™ therapy platform.
How I Manage When My Social Media Friends with Cancer Disappear
I stay in the cancer social media world because it helps me cope, even when friends disappear and I’m left wondering if they’re resting, retreating or gone.
U.S. Centers Seek Namodenoson for Pancreatic Cancer Compassionate Use
U.S. medical centers are seeking FDA authorization for the compassionate use — or expanded access — of Namodenoson for patients with pancreatic cancer.
